Products

The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records

Radiopharmaceuticals

FP-CIT
Indication Diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine carriers in the brain striatum
Features World's first brain imaging tracer related to Parkinson's disease

*DuChemBio owns all FP-CIT license and rights for the technology & clinical data package worldwide except Korea

F-DOPA
Indication Diagnosis of tumors that cannot be diagnosed with conventional FDG, mainly brain tumors and additionally neuroendocrine tumors, pheochromocytoma
Features The world's first Radiopharmaceutical for brain tumor diagnosis with neutralization technology
FES
Indication Diagnosis of metastatic breast cancer and determination of estrogen receptor status
Features The world's first Radiopharmaceutical for breast cancer diagnosis
FACBC
Indication Diagnostic imaging of recurrent or metastatic prostate cancer
Features Radiopharmaceutical for prostate cancer diagnosis
FDG
Indication Diagnosis of tumors that metabolize glucose
Features Radiopharmaceuticals for the diagnosis of tumors, which contributed to the birth of the Radiopharmaceutical industry
Neuraceq
Indication Diagnosis of Alzheimer's Disease by measurement of beta-amyloid distribution and density in the brain
Features First Radiopharmaceutical in Asia for diagnosis of beta amyloid in Alzheimer's disease which is essential for differentiation from vascular dementia
NaF
Indication Diagnostic imaging of bone to identify altered osteogenic active areas
Features Radiopharmaceutical for the diagnosis of bone-related diseases
177Lu-DOTATOC
Indication Treatment of inoperable neuroendocrine tumors originating from the GI tract and pancreas
Features Korea’s first therapeutic Radiopharmaceutical for neuroendocrine tumors

그누보드5
Address 6,7F, 81, Wausan-ro, Mapo-gu, Seoul, Republic of Korea [04041]
Tel 02 332 4868 Fax 02 323 3437

Copyright © 2019 DuChemBio, Inc. All Rights Reserved